Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Metastatic colorectal cancer third-line and beyond has widened materially. Adagrasib and sotorasib carry colorectal indications in KRAS G12C-mutant disease, fruquintinib provides a routine third-line option, and trastuzumab deruxtecan extends ADC reach into HER2-amplified colorectal cancer. The biomarker-pathway investment (RAS, BRAF, MSI status, HER2 amplification, and increasingly ctDNA monitoring) is the addressable-population enabler in late-line colorectal.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?